00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for differentiating HSPCs into megakaryocytes by overexpressing or activating one of 15 genes could help generate platelet-producing megakaryocyte colonies for thrombocytopenia. The method involves two steps: generating megakaryocyte progenitor cells by...
17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; cervical cancer; head and neck cancer; lung cancer; ovarian cancer Patient sample, cell culture and mouse studies suggest inhibiting MAST1 could help treat cisplatin-resistant cancer. In tumor samples from squamous cell carcinoma of...
15:34 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Daiichi's AML candidate leads to median OS of 6.2 months

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported additional data from the Phase III QuANTUM-R trial to treat relapsed or refractory acute myelogenous leukemia (AML) showing that oral quizartinib led to median overall survival (OS), the primary...
15:31 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Daiichi planning NDA for pexidartinib on Phase III TGCT data

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported data from 120 patients with symptomatic advanced tenosynovial giant cell tumors (TGCT) in the Phase III ENLIVEN trial showing that oral pexidartinib (PLX3397) led to an overall response...
19:09 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Astellas' AML candidate gilteritinib

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an NDA for gilteritinib to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation....
19:00 , May 29, 2018 |  BC Extra  |  Company News

FDA reviewing Astellas' AML candidate

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an NDA for gilteritinib to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation....
19:02 , May 25, 2018 |  BC Week In Review  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...